A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years

Trial Profile

A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Etravirine (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 30 Apr 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 09 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top